Compare HCWB & EQS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HCWB | EQS |
|---|---|---|
| Founded | 2018 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8M | 16.2M |
| IPO Year | 2021 | 1995 |
| Metric | HCWB | EQS |
|---|---|---|
| Price | $3.30 | $1.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | ★ 459.2K | 6.9K |
| Earning Date | 05-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $4,099,750.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $1.07 |
| 52 Week High | $7.35 | $2.49 |
| Indicator | HCWB | EQS |
|---|---|---|
| Relative Strength Index (RSI) | 51.53 | 41.64 |
| Support Level | $0.37 | $1.11 |
| Resistance Level | $3.89 | $2.03 |
| Average True Range (ATR) | 0.39 | 0.04 |
| MACD | -0.13 | -0.00 |
| Stochastic Oscillator | 8.94 | 33.64 |
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
Equus Total Return Inc is a United States-based closed-end management investment company. The company invests mainly in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts, and recapitalizations of existing businesses or special situations, and achieves capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.